Diffuse coronary disease: Short- and long-term outcome after percutaneous coronary intervention

Acta Cardiologica

Volumn 68, Issue 2, 2013, Pages 151-160

  Quadri, Giorgio ^a   D'Ascenzo, Fabrizio ^a   Bollati, Mario ^a   Moretti, Claudio ^a   Omedè, Pierluigi ^a   Sciuto, Filippo ^a   Gonella, Anna ^a   Pullara, Alberto ^a   Longo, Giada ^a   Cerrato, Enrico ^a   Colombo, Francesco ^a   Presutti, Davide Giacomo ^a   Colaci, Chiara ^a   De Simone, Virginia ^a   Di Cuia, Marco ^a   Giusto, Federico ^a   Reitano, Clara ^a   Biondi Zoccai, Giuseppe ^b   Sheiban, Imad ^a   Gaita, Fiorenzo ^a  

^a Dermatopathology Section Azienda Ospedaliera Città della Salute e della Scienza   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

BMS; DES; Long lesions; PCI; Restenosis; Small vessels

Indexed keywords

ACETYLSALICYLIC ACID PLUS CLOPIDOGREL; TICLOPIDINE;

AGED; ANGIOCARDIOGRAPHY; ARTICLE; CARDIOVASCULAR MORTALITY; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DEATH; FEMALE; FOLLOW UP; HEART DISEASE; HEART REINFARCTION; HUMAN; MALE; PERCUTANEOUS CORONARY INTERVENTION; REVASCULARIZATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; TREATMENT OUTCOME;

AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY RESTENOSIS; CORONARY VESSELS; DIABETIC ANGIOPATHIES; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PERCUTANEOUS CORONARY INTERVENTION; PROGNOSIS; RETREATMENT; STENTS; TREATMENT OUTCOME;

EID: 84877143913     PISSN: 00015385     EISSN: 03737934     Source Type: Journal    
DOI: 10.1080/ac.68.2.2967272     Document Type: Article

References (33)

1. Dawkins K, Grube E, Guagliumi G, Banning A, Zmudka K, Colombo A, Thuesen L, Hauptman K, Marco J, Wijns W, Popma J, Koglin J, Russell M. T. V. Investigators. Clinical efficacy of polymer-based paclitaxel-eluting stents in the treatment of complex, long coronary artery lesions from a multicenter, randomized trial: support for the use of drug-eluting stents in contemporary clinical practice. Circulation 2005; 112: 3306-3313.
2. Bauters C, Hubert E, Prat A, Bougrimi K, Van Belle E, McFadden E, Amouyel P, Lablanche J, Bertrand M. Predictors of restenosis after coronary stent implantation. J Am Coll Cardiol 1998; 31: 1291-1298.
3. Ardissino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, Angeloni G, Carosio G, Bonizzoni E, Colusso S, Repetto M, Merlini P. SES-SMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA 2004; 292: 2727-2734.
4. Hausleiter J, Kastrati A, Mehilli J, Dotzer F, Schühlen H, Dirschinger J, Schömig A; ISAR-SMART Trial Investigators. Comparative analysis of stent placement versus balloon angioplasty in small coronary arteries with long narrowings (the Intracoronary Stenting or Angioplasty for Restenosis Reduction in Small Arteries [ISAR-SMART] Trial). Am J Cardiol 2002; 89: 58-60.
5. Fajadet J, Wijns W, Laarman G, Kuck K, Ormiston J, Münzel T, Popma J, Fitzgerald P, Bonan R, Kuntz RE; ENDEAVOR II Investigators. Randomized, double-blind, multicenter study of the Endeavor zotarolimus-eluting phosphorylcholine-encapsulated stent for treatment of native coronary artery lesions: clinical and angiographic results of the ENDEAVOR II trial. Circulation 2006; 114: 798-806.
6. Schampaert E, Cohen E, Schlüter M, Reeves F, Traboulsi M, Title L, Kuntz R, Popma JJ; C-SIRIUS Investigators. The Canadian study of the sirolimus-eluting stent in the treatment of patients with long de novo lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115.
7. Stone G, Midei M, Newman W, Sanz M, Hermiller J, Williams J, Farhat N, Mahaffey K, Cutlip D, Fitzgerald P, Sood P, Su X, Lansky AJ; SPIRIT III Investigators. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA 2008; 299: 1903-1913.
8. Colombo A, De Gregorio J, Moussa I, Kobayashi Y, Karvouni E, Di Mario C, Albiero R, Finci L, Moses J. Intravascular ultrasound-guided percutaneous transluminal coronary angioplasty with provisional spot stenting for treatment of long coronary lesions. J Am Coll Cardiol 2001; 38: 1427-1433.
9. Biondi-Zoccai G, Valgimigli M, Sheiban I, Margheri M, Marzocchi A, Prati F, Vischi M, Lettieri C, Violini R, Sardella G, Stabile A, Clementi F, Romeo F, Colombo A, Sangiorgi G. A randomized trial comparing eptifibatide vs. placebo in patients with diffuse coronary artery disease undergoing drug-eluting stent implantation: design of the INtegrilin plus STenting to Avoid myocardial Necrosis Trial. J Cardiovasc Med (Hagerstown) 2008; 9: 957-962.
10. Kim Y, Park S, Lee S, Park D, Yun S, Lee C, Hong M, Kim H, Ko J, Park J, Lee J, Choi S, Seong I, Cho Y, Lee N, Kim J, Chun K, Park SJ; Long-DES-II Study Investigators. Sirolimus-eluting stent versus paclitaxel-eluting stent for patients with long coronary artery disease. Circulation 2006; 114: 2148-2153.
11. Turco M, Ormiston J, Popma J, Hall J, Mann T, Cannon L, Webster M, Mishkel G, O'Shaughnessy C, McGarry T, Mandinov L, Dawkins K, Baim D. Reduced risk of restenosis in small vessels and reduced risk of myocardial infarction in long lesions with the new thin-strut TAXUS Liberté stent: 1-year results from the TAXUS ATLAS program. JACC Cardiovasc Interv 2008; 1: 699-709.
12. Ruygrok P, Webster M, Ardill J, Chan C, Mak K, Meredith I, Stewart J, Ormiston J, Price S. Vessel caliber and restenosis: a prospective clinical and angiographic study of NIR stent deployment in small and large coronary arteries in the same patient. Catheter Cardiovasc Interv 2003; 59(2):165-171.
13. Thygesen K, Alpert JS, White HD; Joint ESC/ ACCF/AHA/WHF Task Force for the Redefinition of Myocardial Infarction, Jaffe AS, Apple FS, Galvani M, Katus HA, Newby LK, Ravkilde J, Chaitman B, Clemmensen PM, Dellborg M, Hod H, Porela P, Underwood R, Bax JJ, Beller GA, Bonow R, Van der Wall EE, Bassand JP, Wijns W, Ferguson TB, Steg PG, Uretsky BF, Williams DO, Armstrong PW, Antman EM, Fox KA, Hamm CW, Ohman EM, Simoons ML, Poole-Wilson PA, Gurfinkel E P, Lopez-Sendon JL, Pais P, Mendis S, Zhu JR, Wallentin LC, Fernández-Avilés F, Fox KM, Parkhomenko AN, Priori SG, Tendera M, Voipio-Pulkki LM, Vahanian A, Camm AJ, De Caterina R, Dean V, Dickstein K, Filippatos G, Funck-Brentano C, Hellemans I, Kristensen SD, McGregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Morais J, Brener S, Harrington R, Morrow D, Lim M, Martinez-Rios MA, Steinhubl S, Levine GN, Gibler WB, Goff D, Tubaro M, Dudek D, Al-Attar N. Universal definition of myocardial infarction. Circulation 2007; 116(22): 2634-2653.
14. Biondi-Zoccai G, Romagnoli E, Agostoni P, Capodanno D, Castagno D, D'Ascenzo F, Sangiorgi G, Modena MG. Are propensity scores really superior to standard multivariable analysis? Contemp Clin Trials 2011; 32(5): 731-740.
15. D'Ascenzo F, Cavallero E, Biondi-Zoccai G, Moretti C, Omedè P, Bollati M, Castagno D, Modena MG, Gaita F, Sheiban I. Use and misuse of multivariable approaches in interventional cardiology studies on drug-eluting stents: a systematic review. J Interv Cardiol 2012; 25(6): 611-621.
16. Kornowski R, Fort S, Almagor Y, Silber S, Lewis BS; Nirtop investigators. Impact of vessel size, lesion length and diabetes mellitus on angiographic restenosis outcomes: insights from the NIRTOP study. Acute Card Care 2008; 10: 104-110.
17. Wykrzykowska J, Serruys P, Onuma Y, De Vries T, Van Es G, Buszman P, Linke A, Ischinger T, Klauss V, Corti R, Eberli F, Wijns W, Morice M, Di Mario C, Van Geuns R, Juni P, Windecker S. Impact of vessel size on angiographic and clinical outcomes of revascularization with biolimus-eluting stent with biodegradable polymer and sirolimus-eluting stent with durable polymer the LEADERS trial substudy. JACC Cardiovasc Interv 2009; 2: 861-870.
18. Ergelen M, Uyarel H, Osmonov D, Ayhan E, Akkaya E, Soylu O, Orhan A, Sayar N, Bozbay M, Turer A, Yildirim E, Yekeler I. Early stent thrombosis in patients undergoing primary coronary stenting for acute myocardial infarction: incidence, a simple risk score, and prognosis. Clin Appl Thromb Hemost 2010; 16: 33-41.
19. Lasala J, Cox D, Dobies D, Baran K, Bachinsky W, Rogers E, Breall J, Lewis D, Song A, Starzyk R, Mascioli S, Dawkins K, Baim DS; ARRIVE 1 and ARRIVE 2 Participating Physicians. Drug-eluting stent thrombosis in routine clinical practice: two-year outcomes and predictors from the TAXUS ARRIVE registries. Circ Cardiovasc Interv 2009; 2: 285-293.
20. Mishkel GJ, Moore AL, Markwell S, Shelton ME. Correlates of late and very late thrombosis of drug eluting stents. Am Heart J 2008; 156: 141-147.
21. Valgimigli M, Campo G, Percoco G, Bolognese L, Vassanelli C, Colangelo S, De Cesare N, Rodriguez A, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro M, Parrinello G, Ferrario M, Moreno R, Piva T, Sheiban I, Pasquetto G, Prati F, Nazzaro MS, Parrinello G, Ferrari R; Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study (MULTISTRATEGY) Investigators. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the MULTISTRATEGY randomized trial. JAMA 2008; 299: 1788-1799.
22. Van der Hoeven B, Liem S, Jukema J, Suraphakdee N, Putter N, Dijkstra J, Atsma D, Bootsma M, Zeppenfeld K, Oemrawsingh P, Van der Wall E, Schalij M. Sirolimus-eluting stents versus bare-metal stents in patients with ST-segment elevation myocardial infarction: 9-month angiographic and intravascular ultrasound results and 12-month clinical outcome results from the MISSION! Intervention Study. J Am Coll Cardiol 2008; 51: 618-626.
23. Tarantini G, Napodano M, Gasparetto N, Favaretto E, Marra M, Cacciavillani L, Bilato C, Osto E, Cademartiri, G. Musumeci, F. Corbetti, R. Razzolini F, Iliceto S. Impact of multivessel coronary artery disease on early ischemic injury, late clinical outcome, and remodeling in patients with acute myocardial infarction treated by primary coronary angioplasty. Coron Artery Dis 2010; 21: 78-86.
24. Lee C, Park D, Lee B, Kim Y, Hong M, Kim J, Park S, Park S. Predictors of restenosis after placement of drug-eluting stents in one or more coronary arteries. Am J Cardiol 2006; 97: 506-511.
25. Kastrati A, Dibra A, Mehilli J, Mayer S, Pinieck S, Pache J, Dirschinger J, Schömig A. Predictive factors of restenosis after coronary implantation of sirolimus- or paclitaxel-eluting stents. Circulation 2006; 113: 2293-2300.
26. Cortese B, Bertoletti A, De Matteis S, Danzi GB, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: A meta-analysis of randomised and observational clinical studies with mid-term follow up. Int J Cardiol 2012; 161: 73-82.
27. Bonello L, De Labriolle A, Lemesle G, Roy P, Steinberg DH, Slottow TL, Xue Z, Torguson R, Kaneshige K, Suddath WO, Satler LF, Kent KM, Lindsay J, Pichard AD, Waksman R. Comparison of outcomes of drug-eluting stents versus bare-metal stents in nonostial proximal left anterior descending coronary arteries. Am J Cardiol 2009; 103: 496-500.
28. Ferenc M, Gick M, Kienzle R P, Bestehorn H P, Werner KD, Comberg T, Zhao M, Buettner HJ, Neumann FJ. Long-term outcome of percutaneous catheter intervention for de novo coronary bifurcation lesions with drug-eluting stents or bare-metal stents. Am Heart J 2010; 159: 454-461.
29. Singh IM, Filby SJ, Elsakr F, Gorodeski EZ, Lincoff AM, Ellis SG, Shishehbor MH. Drug-eluting stents versus bare-metal stents for treatment of bare-metal in-stent restenosis. Catheter Cardiovasc Interv 2010; 76: 257-262.
30. Tamburino C, Di Salvo ME, Capodanno D, Marzocchi A, Sheiban I, Margheri M, Maresta A, Barlocco F, Sangiorgi G, Piovaccari G, Bartorelli A, Briguori C, Ardissino D, Di Pede F, Ramondo A, Inglese L, Petronio AS, Bolognese L, Benassi A, Palmieri C, Patti A, De Servi S. Are drug-eluting stents superior to bare-metal stents in patients with unprotected non-bifurcational left main disease? Insights from a multicentre registry. Eur Heart J 2009; 30:1171-1179.
31. Ormiston JA, Turco MA, Hall JJ, Cannon LA, Yakubov SJ, Lucca MJ, Stone GW, O'Shaughnessy CD, Kozina JA, Gilchrist IC, Bertolet BD, Worthley SG, Underwood PL, Dawkins KD. Long-term benefit of the TAXUS Liberté stent in small vessels and long lesions. - TASIUS ATLAS program-. Circ J 2011; 75: 1120-1129.
32. Diletti R, Onuma Y, Farooq V, Gomez-Lara J, Brugaletta S, van Geuns RJ, Regar E, de Bruyne B, Dudek D, Thuesen L, Chevalier B, McClean D, Windecker S, Whitbourn R, Smits P, Koolen J, Meredith I, Li D, Veldhof S, Rapoza R, Garcia-Garcia HM, Ormiston JA, Serruys PW. 6-month clinical outcomes following implantation of the bioresorbable everolimus-eluting vascular scaffold in vessels smaller or larger than 2.5 mm. J Am Coll Cardiol 2011; 58: 258-264.
33. Pfisterer M, Brunner-La Rocca H, Rickenbacher P, Hunziker P, Mueller C, Nietlispach F, Leibundgut G, Bader F, Kaiser C; BASKET. Long-term benefit-risk balance of drug-eluting vs. bare-metal stents in daily practice: does stent diameter matter? Three-year follow-up of BASKET. Eur Heart J 2009; 30: 16-24.